Marking Persian sturgeon (Acipenser persicus) using new method and tracking them under 10 m depth in the sea

The second phase of the project entitled Marking Persian sturgeon (Acipenser persicus) using new method and tracking them under 10 m depth in the sea was approved in 2004. This project which terminated in April 2009 was carried out during 2004 to 2008 to track coded wire tagged (CWT) sturgeons under 10 m depth. Among the specimens caught, three were juvenile Persian sturgeon tagged in the first phase (2003) were caught in the second phase (2004). The data related to tagging & capture of sturgeon from 2003 to 2008 is included. Totally, 426325 specimens of Persian sturgeon were tagged in 3 weight classes (>3g, 3 to 5g and 6 to 10g). Among the population studied, 101500 of them belonged to specimens of 2003 which were tagged by three hatcheries; Shahid Beheshti, Shahid Rajaee & Shahid Marjani and then released into the rivers (Sefidrud, Tajan & Gorganrud) entering the Caspian Sea. During 2004 to 2008, 324825 specimens were tagged in Shahid Beheshti hatchery and released into the Sefidrud River. Gill net were used to catch the tagged Persian sturgeon specimens under 10m depth. During 2003 to 2008, 3616 Persian sturgeon were captured of which 43 juveniles bore CWT. Among the captured CWT sturgeons, 23 specimens belonged to the 6-10 g weight class, 19 specimens belonged to the 3 to 5g weight class and one sturgeon was >3g. Based on the results, it can be concluded that higher weight at releasing time can lead to higher survival rate and fisheries returns. Some other factors that influence catch rate of CWT sturgeons are as follows: Catch station (highest catch rates in Persian sturgeon juveniles belonged to Chaboksar station), catch season (highest catch rates were recorded in summer which can be attributed to the release of juveniles), catch depth (in winter highest catch occurred at 5 to 10m depth, in other seasons highest catch number was recorded at 3 to 5m depth. Decrease in water temperature is the reason for higher catch numbers at 5 to 10m depth in winter. Also, mesh size can effect on catch rate (highest catch rate belongs to nets with 22mm mesh size). Statistical analysis of results showed significant difference (p<0.05) among the various groups studied. Existence of illegal catch nets in the river can also cause mortality of the released juveniles

Study on the effects of applying garlic (Allium sativum) and Zataria multiflora extracts on Aeromonas hydrophila in Persian sturgeon (Acipenser persicus) fingerling

In order to investigate the effect of ethanol extracts of garlic (Allium sativum) and Zataria multiflora on Aeromonas hydrophila bacteria Persian sturgeon (Acipenser persicus)took the kids to the isolation and identification of bacteria, the minimal inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) of bacteria Aeromonas hydrophila by garlic (Allium sativum) and Zataria multiflora hydroalchoholic extracts to determine the lethal concentrations of hydroalchoholic extracts of garlic (Allium sativum) and Zataria multiflora hydroalchoholic extracts on Persian sturgeon (Acipenser persicus)children , and also to evaluate the efficacy and determine the effective doses of the bacterium Aeromonas hydrophila extracts of in vitro and in vivo were measured. Due to the absence of the Aeromonas hydrophila identification by molecular country in the study of bacteria isolated from sturgeon disease is suspected after detection by screening DNA extraction and molecular By toward action and results by NSBI Aeromonas hydrophila bacteria and Authentication Code NSBI was recorded in Gen Bank JX987090. Based on studies done in vitro (in vitro) in this study, the minimum inhibitory concentrations (MIC) Aeromonas hydrophila bacteria by extracts of garlic and thyme and arrange 1 mg/ml, 0.25mg/ml and the minimum bactericidal concentration (MBC) of bacteria Aeromonas hydrophila by the extracts, respectively, and 2mg/ml, 0.5mg/ml. Study on lethal concentration (LC50) of Zataria multiflora hydroalchoholic extract on fingerlings of Persian sturgeon showed that during 96h and 1h, the LC50 was 766.65 and 9933.44 mg/L, respectively. Also, LC50 of garlic extract during 96h and 1h was 1279.97 and 12624.08 mg/L, respectively. Investigation on white blood cells (WBC) showed significant difference in lymphocyte and neutrophil numbers in different treatments (P0.05). In this study, concentrations ranging from 400 to 1,000 mg/ml of hydroalchoholic extracts of Zataria multfor treating Persian sturgeon (Acipenser persicus) infected with the Aeromonas hydrophila by intraperitoneal injection were determined. Based on the results of the concentration of the extract to 800 mg/ml during shower hour was determined. Assay to determine the concentration of garlic extract on the bacteria in the Persian sturgeon (Acipenser persicus)concentration range of 600 to 1200 mg/ml determine the effective concentration of extract equivalent to 1,000 mg/ml during shower hour was calculated. Study on the pictures taken out from sections of gill, liver and kidny of Persian sturgeon fingerlings (Acipenser persicus) showed that in different doses of garlic (Allium sativum) and Zataria multiflora hydroalchoholic extracts the teretment grups were examined and some microscopic damages observed. They are hyperemia, adhesion in the gill filaments, cell necrosis, melanin pigments in gill primary filaments, cloudy swelling of hepatocytes, liver necrosis, hyperemia and increase in melanin pigments and melano macrophage centers in liver, glomerular changes such as congestion and blocked the dilation of Bowman's space, bleeding, cell necrosis, cloudy swelling of the in kidny

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Background: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings: Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of patients meeting the composite endpoint of progression to invasive mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93–1·05; p=0·79). Interpretation: In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Background: In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation &lt;92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg–800 mg (depending on weight) given intravenously. A second dose could be given 12–24 h later if the patient's condition had not improved. The primary outcome was 28-day mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). Findings: Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0·85; 95% CI 0·76–0·94; p=0·0028). Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50%; rate ratio 1·22; 1·12–1·33; p&lt;0·0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35% vs 42%; risk ratio 0·84; 95% CI 0·77–0·92; p&lt;0·0001). Interpretation: In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the amount of respiratory support and were additional to the benefits of systemic corticosteroids. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

SummaryBackground Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatoryactions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19.Methods In this randomised, controlled, open-label, adaptive platform trial (Randomised Evaluation of COVID-19Therapy [RECOVERY]), several possible treatments were compared with usual care in patients admitted to hospitalwith COVID-19 in the UK. The trial is underway at 176 hospitals in the UK. Eligible and consenting patients wererandomly allocated to either usual standard of care alone or usual standard of care plus azithromycin 500 mg once perday by mouth or intravenously for 10 days or until discharge (or allocation to one of the other RECOVERY treatmentgroups). Patients were assigned via web-based simple (unstratified) randomisation with allocation concealment andwere twice as likely to be randomly assigned to usual care than to any of the active treatment groups. Participants andlocal study staff were not masked to the allocated treatment, but all others involved in the trial were masked to theoutcome data during the trial. The primary outcome was 28-day all-cause mortality, assessed in the intention-to-treatpopulation. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936.Findings Between April 7 and Nov 27, 2020, of 16 442 patients enrolled in the RECOVERY trial, 9433 (57%) wereeligible and 7763 were included in the assessment of azithromycin. The mean age of these study participants was65·3 years (SD 15·7) and approximately a third were women (2944 [38%] of 7763). 2582 patients were randomlyallocated to receive azithromycin and 5181 patients were randomly allocated to usual care alone. Overall,561 (22%) patients allocated to azithromycin and 1162 (22%) patients allocated to usual care died within 28 days(rate ratio 0·97, 95% CI 0·87–1·07; p=0·50). No significant difference was seen in duration of hospital stay (median10 days [IQR 5 to >28] vs 11 days [5 to >28]) or the proportion of patients discharged from hospital alive within 28 days(rate ratio 1·04, 95% CI 0·98–1·10; p=0·19). Among those not on invasive mechanical ventilation at baseline, nosignificant difference was seen in the proportion meeting the composite endpoint of invasive mechanical ventilationor death (risk ratio 0·95, 95% CI 0·87–1·03; p=0·24).Interpretation In patients admitted to hospital with COVID-19, azithromycin did not improve survival or otherprespecified clinical outcomes. Azithromycin use in patients admitted to hospital with COVID-19 should be restrictedto patients in whom there is a clear antimicrobial indication